Discovery of 5-[5-fluoro-2-oxo-1,2- Dihydroindol-(3Z)-ylidenemethyl]-2,4- Dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

L Sun,C Liang,S Shirazian,Y Zhou,T Miller,J Cui,JY Fukuda,JY Chu,A Nematalla,XY Wang,H Chen,A Sistla,TC Luu,F Tang,J Wei,C Tang

DOI: https://doi.org/10.1021/jm0204183

IF: 8.039

2003-01-01

Journal of Medicinal Chemistry

Abstract:To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl- 1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rbeta tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.